Overview:

**COVID-19 RELATION**
RVX-208 also knows as Apabetalone is a potent selective inhibitor of the BET bromodomains. The compound has been thoroughly studied for its role against some key viruses such as HIV-1. By interacting with key bromodomain proteins BRD2 and BRD4, RVX-208 may inhibit the interaction of these proteins with the SARS-CoV-2 protein E, aiding in stopping some key viral processes such as cell entry and replication.**

RVX-208 is a potent BET bromodomain antagonist with IC50 of 0.510 µM for BD2, with approximately 170-fold selectivity over BD1 (1,2). Increases apolipoprotein A-1 and HDL cholesterol in vitro and in vivo (3). Reduces atherosclerosis (4).

References:

1. S Picaud et al. Proc. Natl. Acad. Sci. USA 2013 110: 19754

2. KG McLure et al. PLoS One 2013 8:e83190

3. D Bailey et al. J. Am. Coll. Cardiol. 2010 55:2580

4. R Jahagirdar et al. Atherosclerosis 2014 236:91